Scholarlink

Purpose <p>To investigate the usage status and evaluate the efficacy of intravenous immunoglobulin (IVIG) for the acute treatment of optic neuritis (ON) in Japan.</p> Study design <p>Multicenter retrospective case series.</p> Methods <p>The study subjects were patients with steroid-resistant acute ON in whom IVIG had been initiated between January 2020 and August 2022 at 30 facilities in Japan. The clinical characteristics, visual acuity, and adverse events following IVIG were compared among anti-aquaporin 4 antibody positive ON (AQP4-ON), anti-myelin oligodendrocyte glycoprotein antibody positive ON (MOG-ON), and idiopathic ON (ION).</p> Results <p>The study included sixty-five patients (76 eyes); the main clinical department administering IVIG was ophthalmology (50 cases, 77.0 %). 43 cases had their first ON attack and 22 cases had recurrent ON. Plasmapheresis (PP) was combined in 21 cases. The efficacy endpoint, changes in logarithm of the minimum angle of resolution (logMAR) after IVIG compared with preIVIG, showed statistically significant improvement in the AQP4-ON group at one week, 4 weeks, and 12 weeks after IVIG (p=0.015, p&lt;0.001, p&lt;0.001, respectively). In the MOG-ON group, excluding cases with combined PP, logMAR post IVIG did not improve significantly compared with preIVIG. Among the ION group, compared with preIVIG, logMAR at 4weeks and 12 weeks post IVIG were statistically significant improved (p=0.019, p=0.023, respectively). Adverse events occurred in 7 patients with IVIG. 4 of the 7 patients continued the IVIG treatment, and 3 patients discontinued it within 5 days.</p> Conclusion <p>This study demonstrates that IVIG may be an effective new option for acute treatment of steroid-resistant ON as an add-on to conventional therapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Intravenous immunoglobulin for the acute treatment of refractory optic neuritis in Japan

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年5月16日

查看全文
  • Yohei Takahashi,
  • Takeshi Kezuka,
  • Keigo Shikishima,
  • Akiko Yamagami,
  • Hideki Chuman,
  • Makoto Nakamura,
  • Satoshi Ueki,
  • Akiko Kimura,
  • Masato Hashimoto,
  • Sonoko Tatsui,
  • Nobuyuki Shoji,
  • Hitoshi Ishikawa,
  • Kimiyo Mashimo,
  • Akinori Baba,
  • Yasuyuki Iguchi,
  • Teppei Komatsu,
  • Mayumi Iwasa,
  • Yuko Nakanishi,
  • Mari Sakamoto,
  • Sotaro Mori,
  • Norio Chihara,
  • Akiko Masuda,
  • Yoshihito Mochizuki,
  • Takeo Fukuchi,
  • Yoichiro Shinohara,
  • Kiyotaka Nakamagoe,
  • Shigenari Suzuki,
  • Norito Kokubun,
  • Takahiko Yamanoi,
  • Takashi Iizuka,
  • Hirotaka Yokouchi,
  • Ryutaro Akiba,
  • Junichiro Kizaki,
  • Hidetoshi Onda,
  • Eiji Tomoyori,
  • Yuji Inoue,
  • Yurika Aoyama,
  • Hiromasa Sawamura,
  • Makoto Aihara,
  • Tadashi Matsumoto,
  • Toru Kurokawa,
  • Yuichi Toriyama,
  • Marie Nakamura,
  • Mitsuya Otsuka,
  • Akiko Hikoya,
  • Miwa Komori,
  • Hidehiro Oku,
  • Takahisa Hirokawa,
  • Eri Nakano,
  • Kenji Suda,
  • Atsushi Miki,
  • Katsutoshi Goto,
  • Ken Fukuda,
  • Kayo Sugiura,
  • Norimitsu Fujii,
  • Yuka Sogabe,
  • Koichiro Tamura,
  • Naoya Imanaga

摘要

Purpose

To investigate the usage status and evaluate the efficacy of intravenous immunoglobulin (IVIG) for the acute treatment of optic neuritis (ON) in Japan.

Study design

Multicenter retrospective case series.

Methods

The study subjects were patients with steroid-resistant acute ON in whom IVIG had been initiated between January 2020 and August 2022 at 30 facilities in Japan. The clinical characteristics, visual acuity, and adverse events following IVIG were compared among anti-aquaporin 4 antibody positive ON (AQP4-ON), anti-myelin oligodendrocyte glycoprotein antibody positive ON (MOG-ON), and idiopathic ON (ION).

Results

The study included sixty-five patients (76 eyes); the main clinical department administering IVIG was ophthalmology (50 cases, 77.0 %). 43 cases had their first ON attack and 22 cases had recurrent ON. Plasmapheresis (PP) was combined in 21 cases. The efficacy endpoint, changes in logarithm of the minimum angle of resolution (logMAR) after IVIG compared with preIVIG, showed statistically significant improvement in the AQP4-ON group at one week, 4 weeks, and 12 weeks after IVIG (p=0.015, p<0.001, p<0.001, respectively). In the MOG-ON group, excluding cases with combined PP, logMAR post IVIG did not improve significantly compared with preIVIG. Among the ION group, compared with preIVIG, logMAR at 4weeks and 12 weeks post IVIG were statistically significant improved (p=0.019, p=0.023, respectively). Adverse events occurred in 7 patients with IVIG. 4 of the 7 patients continued the IVIG treatment, and 3 patients discontinued it within 5 days.

Conclusion

This study demonstrates that IVIG may be an effective new option for acute treatment of steroid-resistant ON as an add-on to conventional therapy.